Palvella Therapeutics (PVLA) Shares Outstanding (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Shares Outstanding (Entity) of $14.3 million for Q1 2026, up 29.87% year-over-year from $11.0 million in Q1 2025, and up 15.61% quarter-over-quarter from $12.4 million in Q4 2025.
Palvella Therapeutics (PVLA) Shares Outstanding (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Shares Outstanding (Entity) for 14 consecutive years, with $14.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 29.87% year-over-year to $14.3 million; the TTM figure through Mar 2026 stood at $14.3 million (up 29.87% YoY), while the FY2025 annual figure was $12.4 million, up 456.21% from the prior year.
- Shares Outstanding (Entity) advanced to $14.3 million in Q1 2026 per PVLA's latest filing, from $12.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $14.3 million in Q1 2026 and bottomed at $926225.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $4.4 million across 5 years, with a median of $1.2 million in 2023.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) advanced 0.57% — and 2025, when it soared 790.98%.
- Palvella Therapeutics' Shares Outstanding (Entity) stood at $931488.0 in 2022, then surged by 32.8% to $1.2 million in 2023, then surged by 79.95% to $2.2 million in 2024, then jumped by 456.21% to $12.4 million in 2025, then grew by 15.61% to $14.3 million in 2026.
- Business Quant data shows PVLA's Shares Outstanding (Entity) at $14.3 million in Q1 2026, $12.4 million in Q4 2025, and $11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 14.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.36 Mn |
| Mar 31, 2026 | 13.09 Mn |
| Dec 31, 2025 | 11.25 Mn |
| Sep 30, 2025 | 11.06 Mn |
| Jun 30, 2025 | 11.05 Mn |
| Mar 31, 2025 | 11.01 Mn |
| Dec 31, 2024 | 2.23 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.13 Mn |
| Sep 30, 2023 | 1.24 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 931,488.00 |
| Dec 31, 2022 | 927,150.00 |
| Sep 30, 2022 | 929,962.00 |
| Jun 30, 2022 | 926,562.00 |
| Mar 31, 2022 | 921,388.00 |
| Dec 31, 2021 | 806,838.00 |
| Sep 30, 2021 | 846,625.00 |